Immunovant, Inc.

Immunovant, Inc. is a clinical-stage immunology company developing FcRn-targeted therapies for autoimmune diseases driven by pathogenic IgG antibodies. Its lead candidate, IMVT-1402, and earlier program batoclimab are being advanced for multiple specialty indications, with the company currently focused on clinical development rather than commercial sales.

9.09

9.09

— Immunovant, Inc.
%
Lead FcRn inhibitor programs80% Clinical and pre-commercial development of IMVT-1402 and batoclimab for autoimmune diseases.
Clinical development services15% Trial design, execution, and regulatory preparation for autoimmune indications.
Commercial readiness and launch planning5% Buildout of sales, marketing, distribution, and supply arrangements ahead of approval.

Immunovant does not yet sell approved products, so its near-term “customers” are mainly investigators, clinical trial...

  • Specialist physiciansprimary

    Rheumatologists, neurologists, endocrinologists, dermatologists and other specialists who would prescribe approved FcRn therapies for autoimmune disease patients.

  • Clinical trial sites and investigatorsprimary

    Hospitals and physician practices that enroll and monitor patients in Immunovant's studies and determine execution speed.

  • Third-party payorssecondary

    Commercial insurers and public payors that would determine access, coverage, and utilization after approval.

  • Regulatory authoritiesprimary

    FDA and foreign regulators that review clinical data and determine whether products can be commercialized.

Immunovant is headquartered in the United States and expects its initial commercial organization to be built in the U.S...

  • •United States is the planned initial commercial market
  • •Clinical and regulatory activity is centered in the U.S.
  • •Batoclimab manufacturing includes facilities in the U.S. and South Korea
  • •IMVT-1402 supply depends on third-party CMOs for clinical trials
  • •Potential future collaborations may extend commercialization outside the U.S.

The company’s strategy is to advance IMVT-1402 through clinical development and regulatory approval while preserving...

01
Clinical advancement of IMVT-1402short-term

Approval depends on generating convincing efficacy and safety data in autoimmune indications.

02
Commercial readinessmedium-term

The company needs sales, marketing, distribution and reimbursement capabilities before launch.

03
External manufacturing and supply chain managementshort-term

Clinical and future commercial supply depends on third-party manufacturers and devices.

Immunovant is a pre-revenue biotech, so its value depends on successful clinical outcomes, regulatory approval, and...

critical

Clinical development failure

The company has no approved products and depends on positive trial results for IMVT-1402 and batoclimab.

Scope
Lead programs
Materiality
high
high

Regulatory delay or rejection

Approval is required before any product revenue can be generated.

Scope
FDA and foreign regulators
Materiality
high
high

Manufacturing and supply chain disruption

The company relies on CMOs and third-party suppliers for drug substance, drug product, and devices.

Scope
U.S. and South Korea manufacturing
Materiality
high
high

Commercial competition

Autoimmune disease markets are crowded with approved therapies and pipeline competitors.

Scope
FcRn and autoimmune indications
Materiality
high
high

Financing and dilution risk

The company expects continued net losses and needs capital to fund development and launch.

Scope
Pre-revenue operations
Materiality
high
R&D accruals and clinical trial estimates
Affects quarterly operating expense and loss volatility
Third-party manufacturing commitments
Affects future cash outflows and expense recognition
Revenue recognition for future collaborations
Could materially affect future revenue timing
Stock-based compensation
Affects reported operating loss and dilution analysis

Roivant Sciences Ltd.

ROIV · Pharmaceutical Preparations

Imunon, Inc.

IMNN · Pharmaceutical Preparations

Immunome Inc.

IMNM · Pharmaceutical Preparations

Inmune Bio, Inc.

INMB · Biological Products, (No Diagnostic Substances)

IMMUNIC, INC.

IMUX · Pharmaceutical Preparations

Immunocore Holdings plc

IMCR · Biological Products, (No Diagnostic Substances)

: 28/04/2026